Will Compounded Tirzepatide Be Banned?

On December 19, 2024, the U.S. Food and Drug Administration (FDA) announced that compounding pharmacies must halt the production and distribution of tirzepatide by March 19, 2025. This ruling comes as the shortage of brand-name tirzepatide medications, such as Mounjaro and Zepbound, has officially ended, leading the FDA to reassess and tighten regulations on compounded versions of the drug.

For many patients, compounded tirzepatide has been a more affordable and accessible option for weight loss and diabetes management. Now, with this FDA decision, individuals relying on compounded versions will need to transition to FDA-approved alternatives or explore other treatment options. But what does this change really mean for you? Let’s dive in!

Will Compounded Tirzepatide Be Banned?

Yes, compounded versions of tirzepatide are set to be prohibited in the near future. The U.S. Food and Drug Administration (FDA) has announced that the shortage of tirzepatide injections has been resolved.

Consequently, the FDA has established deadlines for compounding pharmacies to cease the compounding, distribution, and dispensing of tirzepatide:

• For state-licensed compounding pharmacies (under section 503A of the Federal Food, Drug, and Cosmetic Act): Compounding must end by February 18, 2025.

• For outsourcing facilities (under section 503B): Compounding must end by March 19, 2025.

After these dates, the FDA does not intend to exercise enforcement discretion, meaning that compounding tirzepatide will be prohibited.

It’s important to note that while the FDA is providing a grace period to allow for the transition, after the specified deadlines, compounding tirzepatide will be considered a violation of the Federal Food, Drug, and Cosmetic Act. Therefore, compounded tirzepatide will effectively be banned after these dates.

Why Is the FDA Banning Compounded Tirzepatide?

The FDA’s decision to ban compounded tirzepatide is rooted in regulatory policy and safety concerns. According to federal law, compounding pharmacies are only permitted to produce copies of FDA-approved medications if there is a documented shortage. Now that the supply of tirzepatide has stabilized, the FDA has ordered all compounding pharmacies to phase out the production of compounded tirzepatide within 60 to 90 days.

Another major factor is quality control. Unlike FDA-approved medications, compounded drugs are not subject to the same rigorous testing standards. While some pharmacies may follow best practices, no federal oversight ensures consistency in potency, purity, or effectiveness. The FDA has previously issued warnings about contaminated or incorrectly dosed compounded GLP-1 medications, which can pose serious risks to patients.

According to Dr. G, an internal medicine Physician, the FDA’s stance is clear: compounded tirzepatide no longer meets the legal or safety requirements to remain on the market.

“Even if the shortage is ‘resolved’ on paper, I still have patients waiting weeks for their prescriptions. But the FDA’s reasoning is that if Mounjaro and Zepbound are no longer in shortage, compounded tirzepatide can’t be legally produced anymore. That’s it—it’s over.”

What Happens to Patients Using Compounded Tirzepatide?

With compounded tirzepatide being phased out, many patients who relied on it for weight loss and diabetes management will need to find alternative options. This shift presents two major challenges: affordability and access.

For those without comprehensive insurance coverage, brand-name Mounjaro and Zepbound can cost over $1,000 per month out-of-pocket. Many individuals turned to compounded tirzepatide because it was significantly cheaper—often costing hundreds of dollars less per month. With this ban in place, patients who cannot afford the FDA-approved versions may face treatment disruptions.

Another concern is insurance restrictions. Many health plans do not cover GLP-1 medications for weight loss, requiring patients to meet strict criteria or try other medications first. Even for those with coverage, preauthorization requirements and supply chain issues could result in delays, leaving some without their medication for weeks or months.

According to Dr. G, patients who depend on compounded tirzepatide will have to act quickly to secure a new treatment plan:

“What about the folks who just don’t have insurance coverage? Many plans don’t cover obesity medications at all—or they make you jump through endless hoops to get them. People who have been on compounded tirzepatide need to start figuring out what’s next, because after 60 to 90 days, their supply is gone.”

What About Semaglutide? Will It Be Next?

While the FDA’s ban currently applies only to compounded tirzepatide, there is growing speculation that compounded semaglutide could be next. The agency has made it clear that compounded versions of FDA-approved medications are only allowed when there is an active shortage. Since Wegovy and Ozempic have faced persistent supply issues, the FDA has not yet taken action against compounded semaglutide.

However, this could change soon. Manufacturers are ramping up production, and once semaglutide is removed from the shortage list, the FDA is expected to enforce similar restrictions. Patients using compounded semaglutide for weight loss or diabetes management may find themselves in the same situation as those on compounded tirzepatide—forced to switch or discontinue treatment.

Dr. G also noted that, it’s only a matter of time before compounded semaglutide is also banned:

“I am sure, and I’m positive, that semaglutide is close behind. They’re not going to miss a trick. As soon as Novo Nordisk gets its supply chain in order, the FDA will step in, just like they did with tirzepatide.”

How Medicare and Medicaid Could Change GLP-1 Access

One of the biggest challenges with the ban on compounded tirzepatide is the cost of brand-name alternatives. Currently, most Medicare and Medicaid plans do not cover GLP-1 medications for weight loss, making it difficult for many patients to afford Zepbound or Wegovy. However, a proposed rule from the Biden-Harris administration could change this.

In November 2024, the administration introduced a proposal to expand Medicare and Medicaid coverage for anti-obesity medications. If approved, this rule would recognize obesity as a treatable disease and allow millions of Americans to access GLP-1s through federal insurance programs. This would be a major shift in healthcare policy, potentially benefiting 3.4 million Medicare recipients and 4 million Medicaid beneficiaries.

However, the proposal has not yet been finalized, and political opposition could delay or block its implementation. Until these changes take effect, many patients will continue struggling to afford GLP-1 medications—especially those losing access to compounded versions.

Dr. G explains expanding Medicare and Medicaid coverage could be a game-changer for patients:

“The Biden-Harris administration has proposed that Medicare and Medicaid cover anti-obesity medications. If this goes through, millions of people who couldn’t afford GLP-1s before may finally get access. But right now, it’s just a proposal—it hasn’t happened yet.”

What Patients Can Do Now

With compounded tirzepatide being phased out, patients who have depended on it will need to act quickly to find alternatives. For those who can afford it, switching to brand-name Mounjaro or Zepbound is the most straightforward option. However, for individuals facing insurance restrictions or high out-of-pocket costs, navigating this transition may be more challenging.

One approach is to explore manufacturer savings programs. Eli Lilly offers discounts and copay assistance for patients who qualify, which can significantly reduce costs. However, these programs often have strict eligibility requirements, and many individuals may not meet them.

Another option is to monitor upcoming policy changes in Medicare and Medicaid. If federal coverage for GLP-1 medications expands, more patients could gain access to affordable treatments. In the meantime, negotiating with insurance providers and advocating for coverage may help some individuals secure these medications at a lower cost.

For those unable to continue GLP-1 therapy, lifestyle modifications such as dietary changes, exercise, and behavioral support may be necessary to maintain progress. While these strategies are not a direct replacement for medication, they can help manage weight and blood sugar levels for those affected by the ban.

Dr. G also mention that, patients should prepare now to avoid sudden treatment disruptions:

“If you’ve been on compounded tirzepatide, you have about 60 to 90 days before your supplier shuts down production. Start looking into manufacturer savings programs, insurance appeals, and other options now. Don’t wait until the last minute, because access to these medications is going to get even tougher.”

Why Choose Compounded Tirzepatide When You Can Get It for Less from Canada?

One of the biggest reasons patients turned to compounded tirzepatide was cost—the brand-name versions, Mounjaro and Zepbound, are notoriously expensive in the United States. However, with compounded tirzepatide now being phased out, many people are left wondering how they will afford their medications.

What many don’t realize is that buying from Canadian pharmacies can offer significant savings—often at a price even lower than compounded versions in the US. For patients paying out-of-pocket, ordering from Canada could be the best alternative to compounded tirzepatide.

Here’s a price comparison of Mounjaro and Zepbound between our pricing and the average U.S. retail price:

Mounjaro Price Comparison

Prices are approximate and may vary; U.S. prices are based on manufacturer list prices.

Zepbound Price Comparison

Purchasing from a licensed Canadian pharmacy allows patients to legally import a 90-day supply for personal use, which can provide massive savings compared to US prices. Since these are brand-name medications, patients do not have to worry about the inconsistencies that sometimes come with compounded medications.

Conclusion

The FDA’s decision to ban compounded tirzepatide marks a significant shift in the availability of weight loss and diabetes treatments. While this ruling was expected due to the resolution of brand-name shortages, it leaves many patients facing higher costs, stricter insurance requirements, and potential gaps in treatment.

For those who have relied on compounded tirzepatide, this transition will not be easy. However, there are still ways to access affordable GLP-1 medications. Patients can explore Canadian pharmacy options, look into manufacturer savings programs, and stay informed about potential Medicare and Medicaid expansions that could make GLP-1 treatments more accessible.

Frequently Asked Questions